Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 - Slideshow

Structure Therapeutics unveiled positive topline results from its ACCESS II trial and related studies for aleniglipron, an oral GLP-1 receptor agonist, in March 2026. The data demonstrates aleniglipron’s efficacy in weight loss and glucose control, positioning it as a potential competitor to injectable GLP-1 therapies like semaglutide. The company highlighted aleniglipron’s oral formulation as a key differentiator, addressing patient preference for non-injectable treatments in obesity and type 2 diabetes management. ACCESS II trial results showed statistically significant reductions in body weight and improved metabolic markers, reinforcing the drug’s clinical potential. Structure Therapeutics plans to advance aleniglipron into late-stage trials, aiming for regulatory submissions based on these promising findings.